

Seema Nagpal, MD

Address:
875 Blake Wilbur Dr. CC2221
Stanford, CA 94305

Contact Information:
karinh@stanford.edu
650-725-8630

Academic History

Education

1995-1999	Massachusetts Institute of Technology	S.B.	Biology
1999-2004	University of Pennsylvania School of Medicine	M.D.	

Residency and Fellowship Training

2004-2005	University of Iowa Hospitals and Clinics	Intern	Neurosurgery
2005-2006	University of Iowa Hospitals and Clinics	Resident	Neurosurgery
2006-2007	University of California, San Francisco	Intern	Internal Medicine
2007-2010	University of California, San Francisco	Resident	Neurology
2010-2011	Stanford University	Fellow	Neuro-oncology

Licenses and Certifications

2006	California Medical Licence (A96310)
2010	American Board of Psychiatry and Neurology
2015	UCNS Certification in Neuro-oncology

Employment History

2011-present	Clinical Assistant Professor, Division of Neuro-oncology	Stanford University
--------------	--	---------------------

Teaching and Clinical Care

Clinical Teaching

2011-present	Clinic Attending in adult neuro-oncology for medical students, neurology residents, neuro-oncology fellow and oncology fellows
2012-2015	Neurology Ward Attending (2 weeks/year)

Formal Didactics

2006	Brain, Mind, and Behavior Neuro-pathology section facilitator	UCSF SOM
2010	Lecture: <i>Neurologic Complications of Cancer</i>	Stanford Neurology Residency
2011	Lecture: <i>The good news about giving bad news.</i>	Stanford Neurology Residency
2011	Neuro-pathology course facilitator	Stanford SOM
2011	Lecture: <i>Epilepsy: Considerations for the palliative care physician.</i>	Stanford Palliative Care Fellowship
2011	Lecture: <i>How to give bad news.</i>	Stanford Cancer Center Seminar
2012	Lecture: <i>Neuro-oncology.</i>	Introduction to Neurology Seminar, Stanford SOM (NENS206)
2013	Lecture: <i>Neurologic Complications of Cancer.</i>	Stanford Cancer Center Trial Coordinators Series
2013	Lecture: <i>Peripheral Neuropathy: Cost of the Cure?</i>	Stanford Women's Cancer Center Conference

2013	Course Director: Neuro-oncology Lecture Series	Stanford Neurology Residency
2013	Lecture: <i>Medical Management of Glioma</i>	Stanford Neurology Residency
2013	Lecture: <i>Supportive and Palliative Care in Neuro-oncology</i>	Stanford Neurology Residency
2014	Lecture: <i>Neuro-oncology.</i>	Introduction to Neurology Seminar, Stanford SOM(NENS206)
2015	Lecture: <i>The good news about giving bad news.</i>	Stanford Neurology Residency
2015	Lecture: <i>Neurologic Complications of Cancer.</i>	Stanford Neurology Residency
2015	Lecture: <i>Updates in Neuro-oncology</i>	Stanford Cancer Center Education Seminars
2015	Seminar: <i>Neuro-oncology for the Oncology Boards</i>	Stanford Oncology Fellowship
2015	Lecture: <i>Neuro-oncology.</i>	Introduction to Neurology Seminar, Stanford SOM (NENS206)
2015	Lecture: <i>American Society of Clinical Oncology Neuro-oncology Updates</i>	Stanford Cancer Center Education Seminars
2016	Lecture: <i>Neuro-oncology for the Neurology RITE exam and Boards</i>	Stanford Neurology Residency
2016	Seminar: <i>Neuro-oncology for the Oncology Boards</i>	Stanford Oncology Fellowship
2016	Lecture: <i>American Society of Clinical Oncology Neuro-oncology Updates</i>	Stanford Cancer Center Education Seminars
2016	Lecture: <i>Neuro-oncology for the Internist (Stanford SHC)</i>	Stanford Internal Medicine Residency
2016	Lecture: <i>Neuro-oncology for the Internist (VA Palo Alto)</i>	Stanford Internal Medicine Residency
2016	Lecture: <i>Neuro-oncology</i>	Introduction to Neurology Seminar, Stanford SOM (NENS206)
2017	Lecture: <i>Neuro-oncology for the Palliative Care Doctor</i>	Stanford Palliative Medicine Fellowship
2017	Lecture: <i>American Society of Clinical Oncology Neuro-oncology Updates</i>	Stanford Cancer Center Education Seminars
2017	Lecture: <i>Neuro-oncology</i>	Introduction to Neurology Seminar, Stanford SOM (NENS206)
2018	Course Facilitator: <i>Neuro-pathology</i>	Stanford School of Medicine

Trainees and Mentoring

2011-2012	Piia Thomas, MD	Stanford Neuro-oncology Fellow
2012-2013	Reena Thomas, MD	Stanford Neuro-oncology Fellow
2013-2014	Abdul Ajlan, MD	Stanford Neuro-oncology Fellow
2013-2014	Linda Xu, MD	Stanford Neuro-oncology Fellow
2013-2016	Zachary Corbin, MS, MD	Stanford Neuro-oncology Fellow
2016-2017	Sherif Makar, MD	Stanford Neuro-oncology Fellow
2015-current	Tresa MacGranahan, MD	Stanford Neurology Resident & Neuro-oncology Fellow

Administrative Responsibility

2017 - current	Chair, Stanford Neuro-oncology Clinical Research Group
2016 - current	Member, Stanford Scientific Review Committee (SRC)
2015 - 2016	Chair, Stanford Neuro-oncology Clinician Educator Search Committee
2015 - 2016	Member, Stanford CNS Radiation Search Committee
2014 - current	Neuro-oncology Representative, Stanford PathWell (Integrative Cancer Care) Committee
2014 - current	Reviewer, Stanford Data Safety Monitoring Committee
2011 - 2013	Acting Fellowship Director, Adult Neuro-oncology Program
2010 - 2011	Stanford Palliative Care Committee & Clinical Effectiveness Leadership Team
2008 - 2009	Co-Chair, UCSF Resident and Fellows Council
2008 - 2009	Member, UCSF Chief Resident's Council
2008 - 2009	Member, UCSF Graduate Medical Education Committee

Community and Professional Work-Related Service

2004 - current	MIT Class of 1999 Vice-President
2016 - 2018	Section Editor for Neuro-oncology, Current Oncology Reports
2014 - current	Associate Editor for Neurology, Journal of Medical Case Reports
2015 - current	National Comprehensive Cancer Network (NCCN) CNS Section Member
2017 - current	American Radium Society, American College of Radiology Appropriateness Committee CNS Member
2017 - current	Section Editor for Neuro-oncology, Hemeonc.org
2017 - current	Section Editor for Neuro-oncology, Hemeoncreview.com
2014 - current	Stanford PathWell (Integrative Cancer Care) Committee
2016 - current	Abstract Reviewer for Society of Neuro-oncology Meeting (>30)
2016 - current	Reviewer, NEJM (1)
2010 - current	Reviewer, AAN Clinical Practice Guidelines (>5)
2010 - current	Reviewer, Journal of Neuro-Oncology (>50)
2014 - current	Reviewer, Int J of Medical & Pharmaceutical Case Reports (>3)
2013 - current	Reviewer, OncoTargets and Therapy (>5)
2013 - current	Reviewer, Chemotherapy (>5)
2014 - current	Reviewer, PLOS One (>5)
2015 - current	Reviewer, Cancer Treatment Communications (>2)
2016 - current	Reviewer, BMC Cancer (>5)
2016 - current	Reviewer, Int J Rad Onc, Bio, Physics (>2)
2011 - 2013	Journal of Palliative Care Medicine Online Panelist
2010 - 2013	Neurology on the Hill Delegate, AAN
2010 - current	Stanford Neuro-oncology Team Captain, Bay Area Brain Tumor Walk

Professional Membership

2017 - current	American Associate for Cancer Research (AACR)
2017 - current	American Radium Society

2011 - current	Society of Neuro-Oncology (SNO)
2010 - current	American Society of Clinical Oncology (ASCO)
2007 - current	American Academy of Neurology (AAN)
2007 - current	Association of California Neurologists

Awards and Honors

2015	Marquis Who's Who in America
2011	NINDS Clinical Trials Course Participant (by application only)
2009	AAN 2009 Annual Meeting Resident Scholarship Recipient
2003-04	Amer Assoc of University Women Selected Professions Fellowship (Alternate)
2003	National Institute for Diabetes, Digestive and Kidney Disease Research Grant
2002-2003	Sharpe Foundation Educational Research Grant
2002	National Panhellenic Graduate Scholarship
1995-2003	Fermo Giansello Memorial Scholarship
2000	Sigma Kappa Continuing Education Scholarship
1999	Finalist, Capistrano Unified School District Alumnae Hall of Fame
1999	Phi Beta Kappa Honor Society/ Chi Xi Chemistry Honor Society
1999	MIT Dean's Award for Multi-cultural community service

Research

Clinical Trials, Active

2016-current	A Phase 1 study of BPM31510 plus vitamin K in subjects with glioblastoma that has recurred on a bevacizumab-containing regimen Role: Study PI and author
2016-current	A First-in-Human Study of Repeat Dosing with REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death-1 (PD-1), as Single Therapy and in Combination with Other Anti-Cancer Therapies, in Patients with Advanced Malignancies Role: Site PI and co-author of the glioblastoma amendment
2015-current	A Phase 2/3 Randomized, Open Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma Role: Site PI
2016-current	VB-111-215: A phase 3, Randomized, controlled, Double-arm, open-label, multi-center study of VB-111 Combined with bevacizumab vs. bevacizumab monotherapy in patients with recurrent glioblastoma Role: Site PI
2014-current	An open-label phase II trial of NKTR-102 in brain metastases from lung cancer Role: Co-Investigator and Trial Co-author

- 2014-current A phase I/II study to investigate MEDI-4736 in Subjects with Advanced Solid Tumors
Role: Glioblastoma Cohort Co-Investigator
- 2014-current Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma
Role: Site Sub-Investigator
- 2015-current Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
Role: Site Sub-Investigator
- 2015-current A multi-center Phase 2 Open-Label Study Evaluate Safety and Efficacy in Subjects with Melanoma Metastatic to the Brain treated with Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy.
Role: Site Sub-Investigator
- 2016-current Open-Label Study Evaluating Cetuximab-IRDye800 as an Optical Imaging Agent to Detect Neoplasms During Neurosurgical Procedures
Role: Sub-Investigator
- 2014-current A Phase I Trial of Temozolomide and Hypofractionated Radiotherapy in Treatment of Supertentorial Glioblastoma Multiforme
Role: Sub-Investigator
- 2015-current A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects with Recurrent Glioblastoma Multiforme
Role: Site Sub- Investigator

2015-current A Pilot Study Assessing Early Changes in PET/MRI after Bevacizumab (BEV) Administration in Patients in Glioblastoma
Role: Sub-Investigator

Clinical Trials, Complete

2012-2016 Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With MF With Variable CD30 Expression Level
Role: Neurology Co-Investigator, developed neuropathy monitoring section

2012-2014 A Phase II Study of NKTR-102 in Patients with Bevacizumab-Resistant High Grade Glioma
Role: Author, sub-investigator (was not granted PI waiver)

2012-2016 Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma (ACT IV)
Role: Site Sub-Investigator

2012-2016 Phase II Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII Glioblastoma (ReACT)
Role: Site Sub-Investigator

2012-2015 Medi3617: A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
Role: Site Sub-Investigator

2012-2014 A Study of Onartuzumab (MetMab) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Patients With Recurrent Glioblastoma
Role: Site Sub-Investigator

Research Support

2017-2018 NIH SBIR 1R43CA206796 - 01A1 (PI Dorigo, **Protocol Director Nagpal**)
Feasibility Study of New Method of Diagnostic and Prediction of Painful chemotherapy-induced peripheral neuropathy (CIPN).

Bibliography

Peer-Reviewed Publications (24 published, 0 in review, 1 in press)

Robbins P, Behr S, **Nagpal S**. *Interaction of the Bone Morphogenetic Protein Receptor Type IB with Metastatic Prostate Cancer Proteins via the Yeast Two-Hybrid System*. MIT Biology Undergraduate Journal, Volume 2, 1999. <http://web.mit.edu/biojournal/vol2.html>

Huang JH, Simon SL, **Nagpal S**, Nelson PT, Zager EL. *Management of patients with schwannomatosis: report of six cases and review of the literature*. *Surgical Neurology*. 62(4): 353-61; Oct 2004. PMID:15451291

Stein S, Levine J, **Nagpal S**, LeRoux P. *Vasospasm As The Sole Cause of Cerebral Ischemia: How Strong Is The Evidence?* *Neurosurgical Focus*. 21(3), 2006. PMID: 17029341

Nagpal S, Halpern C, Sims C, Calland JF, Gracias VH, Schuster JM, LeRoux PD, Levine JM. *Decompressive Laparotomy to Treat Intractable Cerebral Hypoxia*. *Journal of Trauma: Injury, Infection and Critical Care*. August 2008. PMID: 19088554

Heuer GG, Stiefel MF, **Nagpal S**, Basil AK, Smith D, Zager EL. *Carotid Endarterectomy under Regional Anesthesia: A Primer for the Uninitiated*. *Neurosurgery Quarterly*. 18(3): 201-206, September 2008. doi:10.1097/WNQ.0b013e318182307e

Dhand A, Nakagawa K, **Nagpal S**, Gelfand G, Kim AS, Smith WS, Tihan T. *Cardiac Rupture After Intravenous t-PA Administration in Acute Ischemic Stroke*. *Neurocritical Care*. August 2010. PMID: 20697837

Nagpal S, Harsh G, Recht L. *Bevacizumab Improves Quality of Life in Patients with Recurrent Glioblastoma*. *Chemotherapy Research and Practice*, July 2011. PMID: 22312554

Thomas R, Xu L, Lober RM, Li G, **Nagpal S**. *The Incidence and Significance of Multiple Lesions in Glioblastoma*. *J Neuro Onc*, January 2013. PMID: 23354652

Riess JW, **Nagpal S**. *EGFR mutation status and brain metastases in non-small cell lung cancer: an understudied problem*. *Translational Cancer Research*. Vol 2, No 1, Feb 2013. doi: 10.3978/j.issn.2218-676X.2013.02.06

Riess JW, **Nagpal S**, Neal JW, Wakelee H. *A Patient with ALK Positive NSCLC with Development of Leptomeningeal Carcinomatosis while on Targeted Treatment with Crizotinib*. *JNCCN*. 2013 Apr 1;11(4):389-94. PMID:23584342

Schmiedeskamp H, Andre JB, Straka M, Christen T, **Nagpal S**, Recht LD, Thomas RP, Zaharchuk G, Bammer R. *Simultaneous Perfusion and Permeability Measurements using Combined Spin- and Gradient-Echo MRI*. *Journal of Cerebral Blood Flow and Metabolism*. 2013 May. 33(5):732-43. PMID: 23462570

Atalar B, Modlin L, Choi C, Adler J, Gibbs I, Chang S, Harsh G, Li G, **Nagpal S**, Hanlon A, Soltys S. *Risk of Leptomeningeal Disease in Patients Treated with Stereotactic Radiosurgery Targeting the Post-Operative Resection Cavity for Brain Metastases*. *Int J Radiat Oncol. Biol, Phys*. Nov 2013. PMID 24054875.

Riess JW, **Nagpal S**, Iv M, Zeineh M, Gubens MA, Ramchandran K, Neal JW, Wakelee HA. *Prolonged Survival of Non-Small Cell Lung Cancer Patients With Leptomeningeal Carcinomatosis in the Modern Treatment Era*. *Clinical Lung Cancer*. May 2014, 15 (3) 202-6. PMID:24524822

A Iagaru, E Mitra, M Camila, N Fischbein, **Nagpal S**, Recht LD, Harsh G, Zaharchuk G, G Li, S Ghambir. *Glioblastoma Multiforme Recurrence: An Exploratory Study of (18)F FPPRGD2 PET/CT*. Radiology. Vol 277, Issue 2, November 2015. PMID: 25965900

Andre JB, **Nagpal S**, Hippe DS, Ravanpay AC, Schmiedeskamp H, Bammer R, Paragallo G, Recht LD, Zaharchuk G *Cerebral Blood Flow Changes in Glioblastoma Multiforme Patients Undergoing Bevacizumab Treatment are Seen in Both Tumor and Normal Brain*. The Neuroradiology Journal. April 2015. PMID: 25923677

Pan W, Gu W, **Nagpal S**, Gephart MH, Quake SR. *Brain tumor mutations detected in cerebral spinal fluid*. Clin Chemistry. January 2015. PMID: 25605683

Nagpal S, Recht CK, Bertrand S, Thomas RP, Ajlan A, Pena J, Gershon M, Coffey G, Kunz PL, Li G, Recht LD. *Phase II Pilot Study of Single-Agent Etirinotecan Pegol (NKTR-102) in Bevacizumab-Resistant High Grade Glioma*. J Neurooncol. June 2015. PMID: 25935109

Kim YH, Tavallae M, Sundram U, Salva K, Wood GS, Li S, Rozati S, **Nagpal S**, Krathen M, Reddy S, Hoppe RT, Nguyen-Lin A, Weng WK, Armstrong R, Pulitzer M, Kong C, Advani RH, Horwitz SM. *Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome with Variable CD30 Expression Level: A Multi-Institution Collaborative Project*. J Clin Oncol. November 2015. PMID: 26195720

Li Y, Pan W, Connolly ID, Reddy S, **Nagpal S**, Quake SR, Gephart MH. *Tumor DNA in cerebral spinal fluid reflects clinical course in a patient with melanoma leptomeningeal brain metastases*. J Neuroonc. Epub March 2016. PMID: 26961773

Corbin ZA, Nguyen-Lin, A, Li S, Rahbar Z, Tavallae M, Vogel H, Salva KA, Wood GS, Kim YH, **Nagpal S**. *Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and Sézary Syndrome*. J Neurooncol. March 2017. PMID: 2871282

Pollum EL, Fujimoto D, Wynne J, [et al and 18 others, including **Nagpal S**]. *Phase I/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results*. Int J Radiat Oncol Biol Phys. May 1, 2017; 98 (1): 123-130. PMID: 28586949

Ajlan A, Thomas P, Albakr A, **Nagpal S**, Recht L. *Optimizing bevacizumab dosing in glioblastoma: less is more*. J Neurooncol. 2017 Jun 30. PMID: 28667595

Miller SE, Tummers WS, Teraphongphom N, van den Berg NS, Hasan A, Ertsey RD, **Nagpal S**, Recht LD, Plowey ED, Vogel H, Harsh GR, Grant GA, Li GH, Rosenthal EL. *First-in-human intraoperative near-infrared fluorescence imaging of glioblastoma using cetuximab-IRDye800*. J Neurooncol. April 2018. PMID: 29623552.

Li Y, Liu B, Connolly ID, Kakusa BW, Pan W, **Nagpal S**, Montgomery SB, Gephart MH. *Brief Report: Recurrently Mutated Genes Differ between Leptomeningeal and Solid Lung cancer Brain Metastases*. J Thorac Oncol 2018. PMID: 29604399.

Kang JH, Buckley AD, **Nagpal S**, Fischbein N, Peters KB. *A Diffuse Leptomeningeal Glioneuronal Tumor without Diffuse Leptomeningeal Involvement: Detailed Molecular and Clinical Characterization*. J Neuropathol Exp Neurol. June 2018. PMID: 29931222.

Xie L, **Nagpal S**, Wakelee HA, Li G, Soltys SG, Neal JW. *Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-center Retrospective Study*. The Oncologist. Pending PMID assignment.

Invited Reviews and Chapters (16)

Nagpal S, Glantz MJ, Recht L. *Treatment and Prevention of Secondary CNS Lymphoma*. Seminars in Neurology. 30 (3): 263-272, July 2010. PMID: 20577933

Nagpal S, Recht L. *Treatment and Prophylaxis of the Central Nervous System in Hematologic Malignancy*. Current Treatment Options in Neurology. April 12, 2011. PMID: 21484261

Nagpal S. *The Role of BCNU-polymer Wafers (Gliadel) in the Treatment of Malignant Glioma*. Neurosurgery Clinics of North America, April 2012. 23 (2): 289-295. PMID: 22440872

Nagpal S, Clarke J. *Neoplastic Myelopathy*. Seminars in Neurology, April 2012 (2): 137-145. PMID: 22961188

Nagpal S, Riess J, Wakelee H. *Treatment of Leptomeningeal Spread of NSCLC: A Continuing Challenge*. Current Treatment Options in Oncology, July 2012. PMID: 22836285

Thomas R, Recht L, **Nagpal S**. *Advances in the management of glioblastoma: the role of temozolomide and MGMT testing*. Clinical Pharmacology: Advances and Applications. Dec 27, 2012. PMID: 23293540

Nagpal S, Recht L. *Etirinotecan Pegol*. Drugs of the Future. 2013. 38(4): 227. DOI: 10.1358/dof.2013.038.04.1939287

Nagpal S, Soltys S, Harsh G, Li G, Recht L. *Brain Tumor Management*. Best Practices in Neurological Care. Pages 110-125. February 2014. Doi: 10.2217/ebo.13.309

Nagpal S. *Explaining Leptomeningeal Metastases*. Global Resource for Promoting Cancer Education. <http://cancergrace.org/cancer-treatments/2015/09/23/explaining-leptomeningeal-metastases/> September 23, 2015.

Connolly ID, Li Y, Gephart MH, **Nagpal S**. *The “Liquid Biopsy”: the role of circulating DNA and RNA in central nervous system tumors*. Curr Neurol Neuroscience Reports. 16(3):25. March 2016. PMID: 26838352

Corbin Z, **Nagpal S**. *Leptomeningeal Metastases*. JAMA Oncology. 2(6):839, June 2016. doi:10.1001/jamaoncol.2015.3502

McGranahan T, **Nagpal S**. *A Neuro-oncologist's Perspective on Management of Brain Metastases in Patients with EGFR Mutant Non-small Cell Lung Cancer*. *Current Treatment Options in Oncology*. April 2017; 18(4): 22. PMID: 28391420

Connolly ID, Hixson JD, **Nagpal S**. *An overview of DNA Topoisomerase Inhibitors under development*. *Drugs Fut*. 2016 41 (12): 731.

McGranahan T, Li G, **Nagpal S**. *History and Current State of Immunotherapy in Glioma and Brain Metastases*. *Therapeutic Advances in Medical Oncology*. May 2017; 9 (5): 347-368. PMID: 28529551

Nabors LB, Portnow J, Ammirati M, [et al and 29 others, including **Nagpal S**]. *NCCN Guidelines Insights: Central Nervous System cancers, Version 1.2017*. *JNCCN*. 2017; 15(11):1331-1345 PMID: 29118226.

Shah, JL, Li G, Shaffer JL, Azoulay MI, Gibbs IC, **Nagpal S**, Soltys SG. *Stereotactic Radiosurgery and Hypofractionated Radiotherapy for Glioblastoma*. *Neurosurgery* 2018; 82(1):24-34. PMID: 28605463.

Treatment Guidelines and Institutional Treatment Recommendations

Nagpal S. *Seizures and Epilepsy*. UCSF Medicine Pocket Preceptor. Durand, et al (editors) 2009.

Thomas R, **Nagpal S**. *Neuro-oncology*. Stanford Neurology Resident Handbook, 2013.

Thomas R, **Nagpal S**. *Neuro-oncology*. Stanford Cancer Center Red Book, 2013, 2014.

Nabors LB, Portnow J, Ammirati M, [et al and 29 others, including **Nagpal S**]. *National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines: Central Nervous System Cancers*. Version 1.2016.

Nabors LB, Portnow J, Ammirati M, [et al and 29 others, including **Nagpal S**]. *National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines: Central Nervous System Cancers*. Version 1.2017.

Selected Abstracts (in Poster or Abstract Talk Form)

Nagpal S, Kachur A, Shuman AL, Lustig RA, Busch TM, Evans SM, Koch CJ, Judy KD. *Evaluation of LS11 as a Photodynamic Therapy Agent for Gliomas*. Poster. Soc Neuro Onc, Keynote Colorado 2003.

Nagpal S, Harsh G, Recht L. *Bevacizumab Improves Quality of Life in Patients with Recurrent Glioblastoma*. Poster Talk. Soc Neuro Onc, Montreal 2010.

Bashey S, Krathen M, Sutherland K, Advani R, Hoppe RT, Kim YH, and **Nagpal, S**. *Peripheral neuropathy in MF/SS treated with brentuximab vedotin*. Poster Talk. European Organization for Research and Treatment of Cancer, Vienna 2012.

Riess J, **Nagpal S**, Iv M, Zeineh M, Neal JW, Wakelee HA. *Prolonged Survival with Leptomeningeal Metastases (LM) in Non-Small Cell Lung Cancer (NSCLC) Patients in the Modern Treatment Era*. Poster. Chicago Multidisciplinary Lung Conference, Chicago, 2012.

Nguyen-Lin A, Tavallae M, Li S, **Nagpal S**, Kim YH. *Brentuximab vedotin associated peripheral neuropathy in patients with mycosis fungoides and Sezary syndrome: new lessons & more sensitive tools*. Poster Talk. European Organization for Research and Treatment of Cancer, Paris 2014.

Nagpal S, Recht CK, Imtiaz U, Bertrand S, Thomas RP, Ajlan A, Pena J, Gershon M, Kunz PL, Li G, Recht LD. *Etirinotecan pegol (EP, NKTR-102) in the treatment of high-grade glioma (HGG): A phase 2 trial*. American Society of Clinical Oncology, Chicago 2014.

Thomas R, Ajlan A, Ziskin J, Soltys A, Reddy S, Recht L, **Nagpal, S**. *Complete response to vemurafinib in a patient with metastatic anaplastic xanthroastrocytoma*. Poster. Soc Neuro Onc, Miami 2014.

Ajlan A, Thomas P, **Nagpal S**, Recht L. *Are we using too much Bevacizumab in our GBM patients?* Poster. Soc Neuro Onc, Miami 2014.

Barrett JA, Cai H, Miao J, Murray M, Gable E, Blake D, Krishnan S, Chiocca EA, **Nagpal S**, Raizer J, Yu, J, Lebel F. *Intratumoral regulated expression of IL-12 as a gene therapy approach to treatment of glioma*. Poster. Soc Neuro Onc, San Antonio 2015.

Corbin ZA, Nguyen-Lin, A, Tavallae M, Li S, Kim Y, **Nagpal S**. *A common and long-lasting peripheral neuropathy is associated with brentuximab vedotin treatment of Mycosis Fungoides and Sezary syndrome*. Poster. Soc Neuro Onc, San Antonio 2015.

Li Y, Pan W, Connolly I, **Nagpal S**, Reddy S, Gephart MH, Quake SR. *Monitoring leptomeningeal metastases treatment response using tumor cell free DNA from cerebral spinal fluid*. Poster. AACR, Philadelphia 2015.

Nagpal S, Wakelee HA, Padda SK, Bertrand S, Acevedo B, Holmes-Tisch A, Pagtama JY, Soltys SG, Neal JW. *A Phase II Study of Etirinotecan Pegol (NKTR-102) in Patients with Refractory Brain Metastases and Advanced Lung Cancer*. Poster. IASLC, Vienna 2016.

Nagpal S, Jang TJ, Merchant M, Choi I, Hoch U, Charych D, Recht LD. *Single agent NKTR-214, a biased IL2 pathway agonist, increases immune cell infiltrates in brain tumors and prolongs survival in rodent (rattus) glioblastoma (GBM)*. Poster AACR, Washington, DC 2017.

Gesta S, **Nagpal S**, Dadali T, Merchant M, Jang TJ, Diers AR, Kiebish M, Jiminez J, Vishnudas VK, Narian NR, Sarangarajan R, Recht LD. *BPM31510, a clinical stage metabolic modulator demonstrates therapeutic efficacy in an in vivo C6 rat glioma model and synergizes with temozolomide*. Poster AACR, Washington, DC 2017.

Invited Presentations

2008 *Chronic Meningitis vs. Post-Infectious Meningitis*

UCSF CPC

2009	<i>Ventricular wall rupture after tPA</i>	UCSF Morbidity and Mortality Conference
2010	<i>Bevacizumab prolongs time spent living independently in patients with recurrent GBM</i>	Society of Neuro-oncology, Montreal, Canada
2011	<i>Bevacizumab increases quality and quantity of life in patients with GBM</i>	Duke University, Neuro-oncology
2011	<i>A patient centered approach to neuro-oncology</i>	Grand Rounds, Doctors Hospital Modesto
2011	<i>The promise of anti-angiogenic therapy for primary brain tumors</i>	Breakthroughs in Neurology, San Francisco
2012	<i>Oligodendrogliomas and Astrocytomas</i>	Cancer Prevention Institute of California
2012	<i>Neuro-oncology Case Review</i>	Breakthroughs in Neurology, San Francisco
2013	<i>Neuro-oncology Tumor Board</i>	Multidisciplinary Management of Cancer Conference, Stanford
2013	<i>Medical Management of Glioma: moving toward personalized care</i>	Breakthroughs in Neurology, San Francisco
2013	<i>NKTR-102 in High-Grade Glioma</i>	Nektar R&D Conference, NYC
2013	<i>Glioblastoma: Improved Outcomes Urgently Needed</i>	CME Co-host, San Francisco
2013	<i>Peripheral Neuropathy: The Devil in the Details</i>	Stanford Head & Neck Cancer Support Group
2014	<i>Leptomeningeal Metastases</i>	Tocagen, San Diego
2014	<i>NKTR-102 for High Grade Glioma</i>	Nektar Research Day, San Francisco
2015	<i>Role of Hypofractionated Radiotherapy in the treatment of GBM & Brain Metastases</i>	NYC, NY
2015	<i>A patient centered approach to neuro-oncology</i>	Pacific Cancer Care, Monterey, CA
2016	<i>Neurologic Complications of NSCLC</i>	OmniPrex International Lung Cancer Course, Stanford
2016	<i>The Case for Optimism: Advances in CNS-Directed Cancer Therapy</i>	Breakthroughs in Neurology, San Francisco
2017	<i>Neurologic Complications of NSCLC</i>	OmniPrex International Lung Cancer Course, Stanford
2017	<i>Understanding Molecular Testing in Brain Tumors: How clinically useful is it?</i>	American Academy of Neurology Annual Meeting, Boston
2017	<i>CNS metastases in EGFR mutated lung cancer: the conundrum</i>	MedScape CME NYC, NY

2018	<i>Neuro-oncology Tumor Board</i>	ANCO 18th Multidisciplinary Management of Cancers Conference, Napa
2018	<i>Making Sense of Molecular Markers in Neuro-oncology</i>	American Academy of Neurology, Los Angeles